H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)

July 13, 2026 6:36 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $40.00 price target on Genmab A/S (NASDAQ: GMAB).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found